ES2482290A1 - Inhibidores polares simétricos de colina cinasa con actividad antitumoral - Google Patents

Inhibidores polares simétricos de colina cinasa con actividad antitumoral Download PDF

Info

Publication number
ES2482290A1
ES2482290A1 ES201400466A ES201400466A ES2482290A1 ES 2482290 A1 ES2482290 A1 ES 2482290A1 ES 201400466 A ES201400466 A ES 201400466A ES 201400466 A ES201400466 A ES 201400466A ES 2482290 A1 ES2482290 A1 ES 2482290A1
Authority
ES
Spain
Prior art keywords
translation
machine
legally binding
google translate
choline kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201400466A
Other languages
English (en)
Other versions
ES2482290B1 (es
Inventor
Antonio José ENTRENA GUADIX
Luisa Carlota LÓPEZ CARA
Antonio Espinosa Ubeda
Santiago SCHIAFFINO ORTEGA
Carmen MARCO DE LA CALLE
María Paz CARRASCO JIMÉNEZ
Pablo RÍOS MARCO
Giampetro VIOLA
Rorberta BORTOLOZZI
Giusseppe BASSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Universita degli Studi di Padova
Original Assignee
Universidad de Granada
Universita degli Studi di Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada, Universita degli Studi di Padova filed Critical Universidad de Granada
Priority to ES201400466A priority Critical patent/ES2482290B1/es
Publication of ES2482290A1 publication Critical patent/ES2482290A1/es
Application granted granted Critical
Publication of ES2482290B1 publication Critical patent/ES2482290B1/es
Priority to PCT/ES2015/070437 priority patent/WO2015185780A1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)

Abstract

Inhibidores polares simétricos de colina cinasa con actividad antitumoral. La presente invención se refiere a compuestos polares simétricos de bispiridinio, bisquinuclidinio y bisquinolinio con un linker derivado del 1,2-bis(p-toliloxi)etano inhibidores de colina cinasa, su síntesis y su uso como medicamento antitumoral.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
ES201400466A 2014-06-05 2014-06-05 Inhibidores polares simétricos de colina cinasa con actividad antitumoral Expired - Fee Related ES2482290B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201400466A ES2482290B1 (es) 2014-06-05 2014-06-05 Inhibidores polares simétricos de colina cinasa con actividad antitumoral
PCT/ES2015/070437 WO2015185780A1 (es) 2014-06-05 2015-06-03 Inhibidores polares simétricos de colina cinasa con actividad antitumoral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201400466A ES2482290B1 (es) 2014-06-05 2014-06-05 Inhibidores polares simétricos de colina cinasa con actividad antitumoral

Publications (2)

Publication Number Publication Date
ES2482290A1 true ES2482290A1 (es) 2014-08-01
ES2482290B1 ES2482290B1 (es) 2015-05-19

Family

ID=51228241

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201400466A Expired - Fee Related ES2482290B1 (es) 2014-06-05 2014-06-05 Inhibidores polares simétricos de colina cinasa con actividad antitumoral

Country Status (2)

Country Link
ES (1) ES2482290B1 (es)
WO (1) WO2015185780A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487857B1 (en) 2016-07-25 2021-09-01 Nerviano Medical Sciences S.r.l. Purine and 3-deazapurine analogues as choline kinase inhibitors
JP7178401B2 (ja) 2017-07-11 2022-11-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのピラゾロキナゾリン誘導体
CN116178258B (zh) * 2023-03-15 2023-11-21 中国医学科学院北京协和医院 N-甲基苯胺喹啉类化合物及其合成方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237332A1 (es) * 2004-01-14 2005-07-16 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237332A1 (es) * 2004-01-14 2005-07-16 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Campos et al, Bioorganic & Medicinal Chemistry 2002, vol 10, págs 2215-2231. "Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds", todo el documento *
J Campos et al, Il Farmaco 2003, vol 58, págs 221-229. "Anticancer bisquaternary heterocyclic compounds: a ras-ional design" *

Also Published As

Publication number Publication date
ES2482290B1 (es) 2015-05-19
WO2015185780A1 (es) 2015-12-10

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
TR201907981T4 (tr) Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı.
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
UY35500A (es) Indazoles sustituidos con heteroarilo
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2482290

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150519

FD2A Announcement of lapse in spain

Effective date: 20210915